Merck KGaA, Darmstadt GermanyThis article examines the critical success factors for PEGylated therapies and the decision-making process for when a custom PEG may be warranted rather than an off-the-shelf solution. The essential role of a contract development and manufacturing organization (CDMO) with deep expertise in activated PEG chemistry is highlighted.
Authors: Raymond Behrendt, Silvia Kaden-Vagt, Lotfi Bouchekioua, Merck KGaA, Darmstadt, Germany
Tag Archive for: Merck
Bristol Myers SquibbIn the race to replace MSD’s mega blockbuster pembrolizumab with a more effective bispecific VEGF x PD-(L)1 antibody, German company BioNTech SE has struck a good deal. BioNTech is now developing its Phase III programme BNT327, acquired with the US$950m takeover of Chinese company Biotheus Co Ltd, with Bristol Myers Squibb (BMS) in return for a payment of US$11.1bn.